Bolt Biotherapeutics Q1 2022: Cash $246.8M; BDC-1001 data on track for H2 2022

Bolt Biotherapeutics, Inc.

2023-Q1 EPS reported -$0.64 revenue$813,000

Cash, cash equivalents and marketable securities $246.8M at March 31, 2022; expected to fund operations into 2024.
Collaboration revenue $0.8M from Genmab and Innovent partnerships; R&D expenses $18.4M vs $14.1M prior year.
Loss from operations $23.9M vs $18.4M in Q1 2021, reflecting increased clinical and IND-enabling activities.
Lead ISAC BDC-1001 monotherapy and OPDIVO combo dose escalation on track; data readout expected H2 2022.
IND-enabling activities for CEA-targeted BDC-2034 and Dectin-2 agonist BDC-3042 progressing; BDC-3042 clinical start planned 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.